Peru BPA (GSP) Storage Certification for Droguerias: Compliance Guide
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
Regulatory information verified as of October 29, 2026
1. Key takeaways
Good storage practice (Buenas Prácticas de Almacenamiento, BPA, i.e. GSP) in Peru is governed by R.M. N° 132-2015/MINSA (Manual de Buenas Prácticas de Almacenamiento… en Laboratorios, Droguerías, Almacenes Especializados y Almacenes Aduaneros, published on 2015-03-02) and applies to cold chain devices. The industry commonly organizes re-certification on a 3-year cycle; this cycle is a practical estimate, and the statutory article numbers for certificate validity and the re-certification rhythm are pending verification, with the official publication governing. For a foreign manufacturer, BPA status is therefore an item to be verified at the level of the specific facility actually holding and storing the products, not a general attribute of the market or of the product, and it must be re-examined whenever the storage location or the holding entity changes. In day-to-day operation, BPA compliance is expressed through a small set of verifiable artifacts, including temperature records, receiving and dispatch documentation, cleaning and maintenance logs, and staff training files, all of which are the first documents requested when a regulator arrives without prior notice.
GRZAN treats BPA as a continuing compliance asset of the holding entity: it does not determine whether a sanitary registration can be granted, but it determines whether a granted registration can be maintained stably.
2. Legal basis
| Regulation | Number | Publication date | Provisions / key points |
|---|---|---|---|
| Manual de Buenas Prácticas de Almacenamiento… en Laboratorios, Droguerías, Almacenes Especializados y Almacenes Aduaneros | R.M. N° 132-2015/MINSA | 2015-03-02 | BPA manual; relevant to cold chain devices |
| Manual de Buenas Prácticas de Distribución y Transporte… | R.M. N° 833-2015/MINSA | 2015-12-23 | Good distribution and transport practice manual (Buenas Prácticas de Distribución, BPD, i.e. GDP) and transport |
| Reglamento de Establecimientos Farmacéuticos | D.S. N° 014-2011-SA | 2011-07-27 | Facility licenses and sanitary operating authorization |
| Modificatoria del D.S. N° 014-2011-SA | R.M. N° 966-2019/MINSA | 2019-10-16 | Amends the establishment regulation by ministerial resolution |
| Listado de Cantidades para Muestras de Retención de Productos Farmacéuticos y Dispositivos Médicos | R.M. N° 937-2014/MINSA | 2014-12-03 | List of retention sample quantities |
Regulatory information verified as of October 29, 2026.
3. Expert insights
Insight one: BPA regulates facility conduct, not product attributes. The addressees of R.M. N° 132-2015/MINSA are laboratories, Droguerías (wholesale distributors), specialized warehouses, and customs warehouses, and the regulated content is how these facilities receive, store, keep, and release goods. Mechanically, the same cold chain device placed in different facilities faces the same BPA requirements, while the level of compliance depends on the facility itself. This explains why, when the holding entity is changed, BPA status must be re-verified rather than inherited from the former entity’s certificate.
Insight two: cold chain devices are the high-sensitivity zone of BPA. The manual contains provisions relevant to cold chain devices, and the continuity of the temperature chain is the core of inspections. Mechanically, cold chain requirements turn storage from a static spatial concept into a traceable time series: incoming temperature, in-storage records, outgoing handover, and transport linkage. A gap in any segment breaks the chain. The BPD manual of R.M. N° 833-2015/MINSA (published on 2015-12-23) continues this series on the transport end, and together the two manuals cover the full path from warehouse to delivery.
Insight three: the 3-year re-certification cycle is an industry practice, not a confirmed statutory period. The industry commonly organizes re-certification on a 3-year cycle (a practical estimate); the statutory validity period and re-certification article numbers are pending verification, with the official publication governing. The practical mechanical implication is that the 3-year cycle should not be treated as a safety margin for scheduling, but as an internal control reminder point: re-certification preparation should start earlier than certificate expiry, so that it does not collide with the re-registration (Reinscripción) window of the 5-year sanitary registration (Registro Sanitario, RS) validity under D.S. N° 016-2011-SA (published on 2011-07-27), which would create resource conflicts between two parallel renewal tracks.
Insight four: BPA and retention sample requirements interlock at the data level. R.M. N° 937-2014/MINSA (published on 2014-12-03) sets out the list of retention sample quantities; the samples are physically stored at the establishment, and their storage conditions are in turn governed by BPA. Mechanically, retention samples serve as physical evidence of whether storage conditions are adequate: if samples deteriorate, the cause may lie in the product or in the storage. GRZAN uses sample condition in audits as a reverse indicator of BPA execution quality, because a facility that maintains its retention samples correctly is very likely maintaining its storage, documentation, and inspection readiness to the same standard.
4. Practical recommendations
- Verify the BPA status and certificate dates of the holding entity; for cold chain products, mandatorily check the traceability of temperature records.
- Prepare re-certification on the 3-year cycle (practical estimate) and start internal pre-assessment well before certificate expiry.
- Bring the transport-end requirements of R.M. N° 833-2015/MINSA into carrier management, avoiding warehouse compliance disconnected from transport.
- Configure retention sample quantities under R.M. N° 937-2014/MINSA, and include sample storage conditions in the BPA internal audit scope.
- Re-verify BPA status when changing the holding entity; do not inherit the conclusions of the former entity’s certificate.
- Defer to the official publication for certificate validity and the re-certification rhythm, and keep internal scheduling clear of the 5-year re-registration window.
5. Verification checklist
□ It has been confirmed that the BPA basis is R.M. N° 132-2015/MINSA (2015-03-02).
□ Applicability to cold chain devices has been confirmed and the temperature record chain checked as complete.
□ A re-certification reminder has been set on the 3-year cycle and marked as a practical estimate.
□ The article numbers for certificate validity and re-certification have been marked as governed by the official publication.
□ The transport-end linkage of R.M. N° 833-2015/MINSA and the retention sample quantities of R.M. N° 937-2014/MINSA have been checked.
□ Consistency between the facility licenses (D.S. N° 014-2011-SA, R.M. N° 966-2019/MINSA) and BPA status has been verified.
□ Regulatory information verified as of October 29, 2026.
Regulatory information verified as of October 29, 2026.
GRZAN provides medical device registration support in Peru for manufacturers, importers, and authorized representatives. For inquiries, contact info@grzanglobal.com.
*GRZAN Regulatory Affairs Team*
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us